Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 4 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 84Breast Neoplasms 10Neoplasm Metastasis 7Neoplasms 5Prostatic Neoplasms, Castration-Resistant 4Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Metastatic Castration-resistant Prostate Cancer 3Castration-resistant Prostate Cancer 3Triple Negative Breast Neoplasms 2Castration Resistant Metastatic Prostate Cancer 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Primary Breast Cancer ER+ve 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Progressive Castration-resistant Prostate Cancer 1Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

enzalutamide 3testosterone 17 beta-cypionate 2darolutamide 2abiraterone 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1pamiparib 1olaparib 1lactitol 1fluciclovine F-18 1enfortumab vedotin 1cabazitaxel 1avelumab 1Standard of Care 1Selegiline 1Prednisolone 1Pluvicto 1PSMA-617 1Gonadotropin-Releasing Hormone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-resistant Prostate Cancer × enzalutamide × Clear all
NCT06228053 2025-12-22

SYNERGY-201

Syntrix Biosystems, Inc.

Phase 2 Recruiting
53 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Tulane University

Phase 2 Terminated
8 enrolled 7 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT01942837 2022-10-24

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
67 enrolled 17 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡